REG - ValiRx PLC - Issue of Equity <Origin Href="QuoteRef">VALX.L</Origin>

ValiRxAnnouncement

26/04/2016 12:10

RNS Number : 3772W
ValiRx PLC
26 April 2016
ValiRx Plc
("ValiRx" or the "Company")
Issue of Equity - conversion of loan note
London, UK. 26th April 2016: ValiRx Plc (AIM: VAL), a life science company with a focus on cancer diagnostics and therapeutics for personalised medicine, announces that the Company has received a further conversion notice from Bracknor to convert 90,000 of its Convertible Loan Notes into ordinary shares in the Company.
Following this conversion no Convertible Loan Notes remain outstanding.
Consequently the Company has today conditionally issued and allotted 1,184,211 new ordinary shares in the Company at a price of 7.6 pence per share. The new ordinary shares will rank pari passu with the existing ordinary shares. Application for the 1,184,211 new ordinary shares has been made to the London Stock Exchange and trading in the shares is expected to commence on or around 3 May 2016.
Following the issue of equity above, the Company's issued share capital will comprise of 49,218,931 ordinary shares.
*** ENDS ***
For more information, please contact:
ValiRx plc
Tel: +44 (0) 20 3008 4416
www.valirx.com
Dr Satu Vainikka, Chief Executive
Tel: +44 (0) 20 3008 4416
Tarquin Edwards, Head of Communications.
Tel: +44 (0) 7879 458 364
tarquin.edwards@valirx.com
Mark Treharne, Corporate Development Manager
Tel: +44 (0) 7736 564 686
mark.treharne@valirx.com


Cairn Financial Advisers LLP (Nominated Adviser)
Tel: +44 (0) 20 7148 7900
Liam Murray



Northland Capital Partners Limited (Broker)
Tel: +44 (0) 20 7382 1100
Patrick Claridge / David Hignell (Corporate Finance)
John Howes / Abigail Wayne (Broking)

Notes for Editors 
ValiRx Plc
ValiRx Plc is a biopharmaceutical company developing novel technologies and products in oncology therapeutics and diagnostics. The product focus is in the epigenomic analysis and treatment of cancer, but the technologies can be applied to other fields as well, such as neurology and inflammatory diseases.
The Company has undertaken todevelop a novel and groundbreaking class of therapeutics across a number offields in oncology and has taken its lead compound, Val201, into Phase I/IIclinicaltrials. The Company listed onthe Alternative Investment Market ("AIM") of the London StockExchange in October 2006.
The Company has a pipeline ofother therapeutic drugs, which are currently progressing towards clinicaltrials. The product focus is in the targeted analysis and treatment of cancer,but thetechnologies can be applied to other fields as well, such as neurologyand inflammatory diseases.
It actively manages projectswithin its portfolio as a trading company. The ValiRx business model spreads the risks of life science technologydevelopment by minimising financial exposure andrunning a set of projects todefined commercial endpoints. This maximises returns to shareholders by adding value at the earlier stages where value increases per investment unit are thegreatest.
The Company operates through thefollowing divisional companies:
1. ValiPharma is the therapeuticsdivision, with two embedded technologies primarily directed at the treatment ofcancers.
2. ValiFinn is the biomarkers anddiagnostic development division. ValiRx acquired through its ValiFinn subsidiary, the complimentary TRAC technologylater in the year to strengthen the portfolio.
3. ValiSeek is a joint venturebetween ValiRx and Tangent Ltd to develop Val401 in lung cancer and potentiallyother indications.

This information is provided by RNS
The company news service from the London Stock Exchange
  END
IOEFQLFLQZFBBBQ